North America (2022)

Focus on quality and operational excellence yield strong performance.

Stallergenes Greer North America posted double-digit organic growth in 2022, reflecting our commitment to excellence and our track record of successfully delivering high-quality products to customers.


Continued growth of our veterinary business

Our veterinary business experienced robust growth in 2022, with sales growing double-digit against the prior year. During the year, we successfully launched, a website to raise awareness among pet owners that the signs their pet is showing may be due to allergies and that there are several options for treating them, including allergen immunotherapy. The objective of the site is also to help visitors learn about veterinary dermatologists who specialise in treating allergies and, ultimately, reach out to a veterinary dermatology practice to find out how they may be able to help them and their pet. In an effort to drive pet owners that have pets with potential allergies to this website, we also launched a pet owner social media campaign on both Facebook and Instagram.

The year also marked the return of in-person exhibiting following the pandemic. Stallergenes Greer attended the 2022 edition of the North American Veterinary Dermatology Forum (NAVDF) and sponsored a “residents’ day” prior to the full conference.


Putting patients first

At Stallergenes Greer, serving patients is our top priority. Throughout the year, we maintained investments in our North American operational infrastructure, technology and people to deliver the high-quality bulk allergen extracts, named patient prescriptions and veterinary treatment solutions that our customers deserve.

Stallergenes Greer North America is engaged in a multi-year scale-up to continuously improve the flexibility of operations at its Lenoir (NC, U.S.) facility. Investments include equipment and software to increase efficiency, production quality and output, and reproducibility of our processes. The quality-focused culture of our teams was also reinforced by leadership management training, skills development training, project management and lean six sigma programs.

Meeting increased market demand for high priority allergens

Our double-digit year-on-year growth in North America bears witness to Stallergenes Greer’s superior customer service, comprehensive portfolio of standardised and nonstandardised allergen extracts, and legacy of commitment to the specialist community. Stallergenes Greer maintained positive supply and met the sharp increase in demand for allergen extracts by delivering high priority allergens when they were in short supply. Our San Diego (CA, U.S.) facility, for example, significantly increased the production of house dust mites to ensure supply for patients and the medical community.

Strengthening our integrated approach to source material supply

Stallergenes Greer recently reinforced its internal supply capabilities by purchasing more than 22 hectares of land to produce pollens in Mathiston (MS, U.S.). The acquisition contributes to both de-risking and ensuring greater control of the Group’s supply chain, by reducing the reliance on third-party pollen collectors.

By growing and harvesting our own pollens we also gain better command of the different factors involved in harvesting to produce the purest pollens while enabling the harvesting of pollens that other collectors may not be able to obtain for us. It also provides the opportunity to test-grow new pollens for the benefit of our patients over the long-term. We currently grow, harvest, and collect over 75 different pollens in Mathiston.

Providing training to healthcare professionals

Stallergenes Greer provides training for healthcare professionals regarding pharmaceutical compounding and sterile preparations under Chapter 797 of USP (U.S. Pharmacopeia). USP, a non-profit organisation, establishes documentary and reference standards for medicines, food ingredients, dietary supplement products and ingredients which are used by U.S. regulatory agencies to help ensure that the forementioned products are of the appropriate identity, strength, quality, purity, and consistency. Each year, at the American College of Allergy, Asthma, and Immunology (ACAAI) Stallergenes Greer trains physicians regarding the guidelines which must be followed for aseptic preparation and compounding.

Canada, set for growth

In 2022, our Canadian affliate continued to transform and invest in its quality systems to maintain excellence in quality assurance. The objectives were to: instil a quality mindset throughout the organisation, ensure we were properly resourced with qualified personnel, continue to enhance our quality management system incorporating good manufacturing practices (GMP), quality risk management and monitoring procedures and conduct robust shipping and temperature mapping studies. All the objectives were met at the end of 2022 and management will continue to build upon this transformation in the future.

The Canadian organisation also pursued the deployment of talent development plans to prepare top talent for their next role, ensure succession planning to accommodate future growth, provide a great place to work and retain top talent.